scholarly journals Anisocoria as a side effect of paclitaxel treatment

2021 ◽  
Vol 34 (4) ◽  
Author(s):  
Jana Halámková ◽  
Dagmar Adámková Krákorová ◽  
Regina Demlová
Keyword(s):  
Side Effect ◽  
Paclitaxel Treatment

scholarly journals Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3915
Author(s):  
Leni van Doorn ◽  
Mandy M. van Rosmalen ◽  
Wendy M. van der Deure ◽  
Esther Oomen-de Hoop ◽  
Robert Porrazzo ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Side Effect ◽  
Chemotherapeutic Agent ◽  
Relative Difference ◽  
High Impact ◽  
Scalp Cooling ◽  
Weekly Dose ◽  
Geometric Means ◽  
Blood Samples ◽  
Paclitaxel Treatment

Chemotherapy-induced alopecia (CIA), a side effect with high impact, can be prevented by cooling the scalp during the administration of some cytotoxic drugs. However, the effects of this prolonged scalp cooling on the pharmacokinetics of chemotherapy have never been investigated. In this study, we compared the pharmacokinetics of the widely used chemotherapeutic agent paclitaxel (weekly dose of 80–100 mg/m2) in female patients with solid tumors using concomitant scalp cooling (n = 14) or not (n = 24). Blood samples were collected in all patients for pharmacokinetic analyses up to 6 h after one course of paclitaxel administration. The primary endpoint was the clearance (L/h) of paclitaxel. Paclitaxel clearance—expressed as relative difference in geometric means—was 6.8% (90% CI: −16.7% to 4.4%) lower when paclitaxel was administered with concomitant scalp cooling versus paclitaxel infusions without scalp cooling. Within the subgroup of patients using scalp cooling, paclitaxel clearance was not statistically significantly different between patients with CIA (alopecia grade 1 or 2) and those without CIA. Hence, scalp cooling did not negatively influence the clearance of paclitaxel treatment.

scholarly journals Functional and anatomical characterization of a non-leaking bilateral cystoid macular edema induced by paclitaxel therapy for ovarian cancer: a case report

2019 ◽  
Author(s):  
Stephan Hoffmann ◽  
David Ganster ◽  
Patrick Sidoroff ◽  
Stefan Mennel
Keyword(s):  
Ovarian Cancer ◽  
Macular Edema ◽  
Side Effect ◽  
Cystoid Macular Edema ◽  
Vision Loss ◽  
Early Recognition ◽  
Fluorescence Angiography ◽  
Drug Induced ◽  
Rare Side Effect ◽  
Paclitaxel Treatment

Abstract Abstract: Background: Paclitaxel is a member of the taxane family used for cancer therapy. Ovarian cancer is treated with Paclitaxel in first- and in second- line therapy. Cystoid macular edema without fluorescein leakage is a rare side effect of Paclitaxel treatment. Case presentation: We report the case of a 59-year-old female with ovarian cancer treated with paclitaxel. The patient received 21 cycles of adjuvant chemotherapy and was presented with bilateral gradual vision loss due to macular edema after paclitaxel treatment. Optical coherence tomography revealed a bilateral cystoid macular edema. Fluorescence angiography demonstrated the unusual finding of non-leakage in the late phases of the angiogram. Microperimetric findings of both eyes confirmed the visual deficits. After cessation of the paclitaxel therapy, vision, OCT and microperimetric findings returned to normal. Also, color vision testing demonstrated no persistent defect after therapy cessation. Conclusion: Paclitaxel induced bilateral maculopathy is a rare side effect of chemotherapy. Cessation of the Paclitaxel drug therapy leads to complete functional and anatomical resolution of drug induced side effects. Vision, microperimetric defects, color perception as also anatomical defects detected by OCT change to normal after drug cessation. Taxane induced bilateral maculopathy is a rare disease which should be known by ophthalmologists as also oncologists. Paclitaxel therapy must be counseled to report any vision problems during the treatment period because early recognition of a rare non leaking CME can facilitate appropriate intervention to reverse visual compromise and minimize any potential long-term ophthalmologic sequelae.

Conjunctival oedema: a side-effect of cyclosporin toxicity and a consequence of obesity

1996 ◽  
Vol 135 (1) ◽  
pp. 146-147 ◽  
Author(s):  
E. Papadavid ◽  
J. Yell ◽  
T.J. Ryan
Keyword(s):  
Side Effect
Sign in / Sign up

Export Citation Format

Share Document